Probiotics for Clostridium difficile - Associated diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1212-1221

  Segarra Newnham, Marisel ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile diarrhea; Lactobacillus; Probiotics; Saccharomyces

Indexed keywords

AMPHOTERICIN B; CULTURELLE; CYCLOPHOSPHAMIDE; FLORASTOR; FLUCONAZOLE; LACTOBACILLUS RHAMNOSUS GG PROBIOTIC; PROBIOTIC AGENT; SACCHAROMYCES BOULARDII PROBIOTIC; STEROID; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTEREMIA; BACTERIAL STRAIN; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONSTIPATION; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; ENDOCARDITIS; EVALUATION; FUNGEMIA; HUMAN; IMMUNE DEFICIENCY; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS RHAMNOSUS GG; LIVER ABSCESS; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SACCHAROMYCES BOULARDII; SIDE EFFECT; THIRST;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS; LACTOBACILLUS; PROBIOTICS; RECURRENCE; SACCHAROMYCES;

EID: 34547154687     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K110     Document Type: Review

References (72)

1. Bouza E, Muñoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005;11(suppl 4):57-64.
2. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile - associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57.
3. Broussard EK, Surawicz CM. Probiotics and prebiotics in clinical practice. Nutr Clin Care 2004;7:104-13.
4. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002;23:653-9.
5. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50.
6. Buchner AM, Sonnenberg A. Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci 2002;47:201-7.
7. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile - associated enteric disease. Ann Intern Med 2006;145:758-64.
8. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998;16:292-307.
9. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol 2006;40:249-55.
10. Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am 2006;35:355-65. DOI 10.1016/j.gtc.2006.03.005
11. Dendukuri N, Costa V, McGregor M, Brophy J. The use of probiotics in the prevention and treatment of Clostridium difficile diarrhea. www.mcgill.ca/files/tau/PROBIOTICS_Report_5Final.pdf (accessed 2007 Jan 29).
12. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-7.
13. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005;54:101-11.
14. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile - associated diarrhea and colitis. Am J Gastroenterol 1997;92: 739-50.
15. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152-3.
16. Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile - associated disease. Ann Pharmacother 2006;40:2155-63. Epub 5 Dec 2006. DOI 10.1345/aph.1H332
17. FAO/WHO Working Group report. Guidelines for the evaluation of probiotics in food, www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf (accessed 2007 Jan 29).
18. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996;275:870-6.
19. Hopkins MJ, MacFarlane GT. Changes in predominant bacterial populations in human faeces with age and Clostridium difficile infection. J Med Microbiol 2002;51:448-54.
20. McFarland LV. Effective probiotic therapy: disease states to target for probiotics. CE monograph, expires 2008 Jul 7. www.freece.com/freece/ Article_Dynamic.asp?dbArticleID=97&dbRegID+&index (accessed 2007 Jan 29).
21. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7:59-62.
22. Wullt M, Hagslätt MLJ, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile - associated diarrhoea: a double-blind, placebo controlled trial. Scan J Infect Dis 2003;33:365-7.
23. Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005;24:31-40. DOI 10.1007/s10096-004-1253-y
24. Alvarez-Olmos MI, Obserhelman RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis 2001;32:1567-76.
25. de Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000:71:405-11.
26. Elmer GW. Probiotics: "Living drugs." Am J Health Syst Pharm 2001; 58:1101-9.
27. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995;21:224-6.
28. Gorbach SL, Chang T-W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG (letter). Lancet 1987; 2:1519.
29. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease (letter). J Med Microbiol 2005;54:905-6. DOI 10.1099/jmm.0.46096-0
30. Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006;83:1256-64.
31. Kunz AN, Fairchock MP, Noel JM. Lactobacillus sepsis associated with probiotic therapy (letter). Pediatrics 2005;116:517-8. DOI 10.1542/peds.2005-0475
32. Husni RN, Gordon SM, Washington JA, Longworth DL. Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis 1997; 25:1048-55.
33. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73(suppl):465S-70S.
34. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
35. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81. DOI 10.1542/peds.2004-2137
36. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JMT. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999;5:290-2.
37. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004;38:457-8.
38. DeGroote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80. DOI 10.1097/01.inf. 0000154588.79356.e6
39. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004;38:62-9.
40. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002;35:1155-60.
41. Saxelin M, Chuang N-H, Chassy B, et al. Lactobacilli and bacteremia in Southern Finland, 1989-1992. Clin Infect Dis 1996;22:564-6.
42. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8. Erratum 1994;272:518.
43. Smith D, Metzgar D, Wills C, Fierer J. Fatal Saccharomyces cerevisiae aortic graft infection. J Clin Microbiol 2002;40:2691-2.
44. Herbrecht R, Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005;40:1635-7.
45. Muñoz P, Bouza E, Cunca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34.
46. McCullough MJ, Clemons KV, McCusker JH, Stevens DA. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998;36:2613-7.
47. McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae (letter). Clin Infect Dis 1996;22:200-1.
48. Eddy JT, Stamatakis MK, Makela EH. Saccharomyces boulardii for the treatment of Clostridium-difficile-associated colitis. Ann Pharmacother 1997;31:919-21.
49. Kimmey MB, Elmer GW, Surawicz CM, McFarland LV. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 1990;35:897-901.
50. Surawicz CM, McFarland LV, Elmer G, Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989;84:1285-7.
51. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41: 5340-3. DOI 10.1128/JMC.4.11.5 340-5343.2003
52. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19:16-20.
53. Graf C, Gavazzi G. Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation (letter). J Infect 2007;54:310-1. Epub 20 Mar 2006. DOI 10.1016/j.jinf.2006.01.019
54. Lherm T, Monet C, Nougière B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28:797-801. DOI 10.1007/s00134-002-1267-9
55. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998;105:71-2.
56. Riquelme AJ, Calvo MA, Guzmán AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003;36:41-3.
57. Niault M, Thomas F, Prost TJ, Ansari FH, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii (letter). Clin Infect Dis 1999;28:930.
58. Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21:113-5.
59. Fredenucci I, Chomarat M, Boucaud C, Flandrois JP. Saccharomyces boulardii fungemia in a patient receiving ultra-levure therapy. Clin Infect Dis 1998;27:222-3.
60. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000;8:504-5. DOI 10.1007/s005209900123
61. Perapoch J, Planes AM, Querol A, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 2000;19:468-70. DOI 10.1007/s100960000295
62. Rijnders BJA, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host (letter). Intensive Care Med 2000; 26:825.
63. Lungarorri MS, Mezzetti D, Radicioni M. Methaemoglobinaemia with concurrent blood isolation of Saccharomyces and Candida (letter). Arch Dis Child Fetal Neonatol Ed 2003;88:F446.
64. Henry S, D'Hondt L, Andre M, Holemans X, Canon JL. Saccharomyces cerevisiae fungemia in a head and neck cancer patient. Acta Clin Belg 2004;59:220-2.
65. Cherafi S, Robberecht J, Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg 2004;59:223-4.
66. Burkhardt O, Köhnlein T, Pletz MW, Welte T. Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 2005;37:69-72. DOI 10.1080/00365540510026454
67. Fiore NF, Conway JH, West KW, Kleiman MB. Saccharomyces cerevisiae infections in children. Pediatr Infect Dis J 1998;17:1177-9.
68. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41:1559-68.
69. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002;16:1461-7.
70. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in the prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324: 1361-6.
71. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22.
72. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000;95(suppl):S11-3.